Voriconazole Therapeutic Drug Monitoring

ABSTRACT We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship (P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 μg/ml, while disease progressed in 44% (n = 18) of patients with concentrations below 2.05 μg/ml.

[1]  J. Perfect,et al.  Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. , 2005, Transplantation.

[2]  R. Service.  Going From Genome to Pill , 2005, Science.

[3]  J. Englund,et al.  Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Bartelt,et al.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Nakashima,et al.  Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.

[6]  B. Ljungberg,et al.  Pharmacokinetic Studies in Hepatic Impairment: is the Maddrey function a Eelevant Marker? , 2004, Clinical pharmacology and therapeutics.

[7]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[8]  J. Medicis,et al.  Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer , 2003, Journal of clinical pharmacology.

[9]  N. Wood,et al.  Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.

[10]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[11]  N. Wood,et al.  Safety of voriconazole and dose individualization. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  B. Potoski,et al.  The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[14]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[15]  H. Lazarus,et al.  Safety and Pharmacokinetics of Oral Voriconazole in Patients at Risk of Fungal Infection: A Dose Escalation Study , 2002, Journal of clinical pharmacology.

[16]  M. Barclay,et al.  The therapeutic monitoring of antimicrobial agents. , 2001, British journal of clinical pharmacology.

[17]  C. Leutner,et al.  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole , 1999, Mycoses.

[18]  G. Cheymol,et al.  Optimisation of Itraconazole Therapy Using Target Drug Concentrations , 1998, Clinical pharmacokinetics.

[19]  S. Radford,et al.  In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens , 1997, Antimicrobial agents and chemotherapy.

[20]  W. Craig,et al.  Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. , 1996, The Pediatric infectious disease journal.

[21]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[22]  M. Oellerich,et al.  Individualization of 5-fluorocytosine therapy. , 1994, Chemotherapy.

[23]  M. Schäfer-Korting.  Pharmacokinetic Optimisation of Oral Antifungal Therapy , 1993, Clinical pharmacokinetics.

[24]  J J Schentag,et al.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[25]  T. Walsh,et al.  Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[27]  D. Grasela,et al.  Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections , 2001 .

[28]  R. Yeates,et al.  Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. , 1994, Drugs under experimental and clinical research.

[29]  H. Prümke,et al.  [Therapeutic drug monitoring of itraconazole--a report of experiences]. , 1994, Mycoses.